HOWL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 115192 min ago

@ $6.85

Išleistas: 9 vas. 2024 @ 17:56

Grąža: -6.35%

Ankstesnis signalas: vas. 8 - 18:03

Ankstesnis signalas: Pardavimas

Grąža: 3.95 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 18:49):

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer...

Stats
Šios dienos apimtis	43 126.00
Vidutinė apimtis	227 943
Rinkos kapitalizacija	274.16M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-0.350 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.11
ATR14	$0.0490 (0.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Atkins Michael B.	Buy	35 000	Stock Option (right to buy)
2024-01-04	Atkins Michael B.	Sell	0	Common Stock
2024-01-02	Trost Timothy W.	Buy	150 000	Stock Option (right to buy)
2024-01-02	Lubman Ellen	Buy	131 900	Stock Option (right to buy)
2024-01-02	Isaacs Randi	Buy	200 000	Stock Option (right to buy)

INSIDER POWER
99.27
Last 97 transactions
Buy: 45 258 272 \| Sell: 143 550 934

Tūris Koreliacija

Ilgas: 0.01 (neutral)

Trumpas: 0.07 (neutral)

Signal:(53.528) Neutral

Werewolf Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM	0.939
APOP	0.918
FEYE	0.897
SVOK	0.88
TLGT	0.879
SVAC	0.874
GAINL	0.874
PAIC	0.861
SYBX	0.854
TDAC	0.851

10 Labiausiai neigiamai susiję koreliacijos
MMAC	-0.959
AMRB	-0.922
BOCH	-0.893
NETE	-0.888
RGP	-0.851
SBBP	-0.823
SHSP	-0.809

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Werewolf Therapeutics, Koreliacija - Valiuta/Žaliavos

0.44
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.06
( neutral )

0.58
( weak )

0.42
( neutral )

Werewolf Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$19.94M
Bruto pelnas:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2023
Pajamos:	$19.94M
Bruto pelnas:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2022
Pajamos:	$16.40M
Bruto pelnas:	$13.89M (84.70 %)
EPS:	$-1.790

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.57

Financial Reports:

No articles found.

Werewolf Therapeutics,

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.